Conclusion: This meta‐analysis, encompassing 515 patients from four RCTs, demonstrated that GLP‐1R agonists are associated with a slower deterioration of motor symptoms and cognitive functions in patients with mild to moderate Parkinson's disease. Here, GLP1R is linked to Parkinson disease.